

FIRST QUARTER 2023 RESULTS

TOTAL COMPANY

BUSINESS HIGHLIGHTS



- New data show superiority of TriCtipvice compared to medical therapy for tricuspid regurgitation, with signi cant improvement in quality of life
- Announced agreement to acquire Cardiovascular Systems, Inc. (CSI), which would add to our leading vascular device of erings



*Organic sales growth excludes impact of foreign exchange, as well as the impact of exiting the pediatric nutrition business in China. For full nancial data and reconcilitation of non-GAAP measures, please see our press release dated April 19, 2023, available at www.abbottinvestor.com